Bladder cancer trial combines two treatments to fight tough tumors
NCT ID NCT02560636
First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This early-stage trial tests the safety and best dose of an immunotherapy drug (pembrolizumab) given alongside radiation for people with advanced bladder cancer. About 34 participants will receive the drug before and during radiation, then continue it for up to a year. The goal is to see if this combination can control the cancer better than either treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.